ACTIVE_NOT_RECRUITING

Quatera 700 vs. Centurion

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Phacoemulsification is the most common treatment for cataract surgery in the developed countries and over the years it gained importance due to several factors: small incision, surgery performed under topical anesthesia - which reduce injection-related complications - short recovery time, low post operatory induced astigmatism, and low incidence of surgical complications, when compared to the conventional surgeries. The study evaluates 2 different phacoemulsification devices in patients undergoing routine cataract surgery in both eyes.

Official Title

Evaluation and Clinical Outcomes After Routine Cataract Surgery With the Quatera® 700 and the Centurion® Vision System

Quick Facts

Study Start:2024-01-10

Study Completion:2025-11-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06225362

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subject is undergoing bilateral lens extraction with implantation of a posterior chamber intraocular lens. * Gender: Males and Females. * Age: 50 to 80 years old. Solomon KD, DeOliveira A, Sandoval HP 4 CONFIDENTIAL CEP 23-002 Version 1.0/27Jul2023 * Willing and able to provide written informed consent for participation in the study * Willing and able to comply with scheduled visits and other study procedures. * Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 1 to 30 days between surgeries * Subjects requiring an IOL power in the range of +10.0 D to +30.0 D only. * Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.	* Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc. * Uncontrolled diabetes. * Use of any systemic or topical drug known to interfere with visual performance. * Contact lens use during the active treatment portion of the trial. * Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. * Clinically significant corneal dystrophy. * Corneal irregularities potentially affecting visual acuity: keratoconus, corneal dystrophy, corneal opacities. * Endothelial cell count less than 1500 cells/mm2 * History of chronic intraocular inflammation. * History of retinal detachment. * Femtosecond arcuates at time of surgery. * Femtosecond laser assisted cataract surgery in one eye only. * Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. * Previous intraocular surgery. * Previous radial keratoromy (RK). * Previous keratoplasty * Pupil abnormalities * Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e. LASIK) * Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc). * Other ocular procedures at the time of the cataract extraction (i.e., iStent) * Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. * Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Inclusion Criteria

Exclusion Criteria

* Subject is undergoing bilateral lens extraction with implantation of a posterior chamber intraocular lens.
* Gender: Males and Females.
* Age: 50 to 80 years old. Solomon KD, DeOliveira A, Sandoval HP 4 CONFIDENTIAL CEP 23-002 Version 1.0/27Jul2023
* Willing and able to provide written informed consent for participation in the study
* Willing and able to comply with scheduled visits and other study procedures.
* Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 1 to 30 days between surgeries
* Subjects requiring an IOL power in the range of +10.0 D to +30.0 D only.
* Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

* Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
* Uncontrolled diabetes.
* Use of any systemic or topical drug known to interfere with visual performance.
* Contact lens use during the active treatment portion of the trial.
* Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
* Clinically significant corneal dystrophy.
* Corneal irregularities potentially affecting visual acuity: keratoconus, corneal dystrophy, corneal opacities.
* Endothelial cell count less than 1500 cells/mm2
* History of chronic intraocular inflammation.
* History of retinal detachment.
* Femtosecond arcuates at time of surgery.
* Femtosecond laser assisted cataract surgery in one eye only.
* Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
* Previous intraocular surgery.
* Previous radial keratoromy (RK).
* Previous keratoplasty
* Pupil abnormalities
* Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e. LASIK)
* Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
* Other ocular procedures at the time of the cataract extraction (i.e., iStent)
* Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
* Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Contacts and Locations

Study Locations (Sites)

Carolina Eyecare Physicians, LLC

Mount Pleasant, South Carolina, 29464

United States

Collaborators and Investigators

Sponsor: Carolina Eyecare Physicians, LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-10

Study Completion Date2025-11-30

Study Record Updates

Study Start Date2024-01-10

Study Completion Date2025-11-30

Terms related to this study

Additional Relevant MeSH Terms

Cataract